Parkinson's Disease

Parkinson’s Disease – Medical Student Study Guide

Definition

Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disorder characterized clinically by a combination of bradykinesia plus at least one of rest tremor, muscular rigidity, or postural instability, and pathologically by degeneration of dopaminergic neurons in the substantia nigra pars compacta with intraneuronal Lewy bodies.

Epidemiology

PD is the second most common neurodegenerative disease after Alzheimer’s disease and the most common cause of parkinsonism.

• Typical age of onset: 55–65 years; incidence increases with age.
• Slight male predominance.
• Most cases are sporadic; 5–10% are familial with identifiable monogenic mutations (e.g., LRRK2, PARK2, SNCA, PINK1).
• Risk factors: advanced age, family history of PD, possible environmental toxin exposure (e.g., pesticides, rural living), traumatic brain injury.
• Potential protective factors (observational): smoking, caffeine intake, physical activity.

Pathophysiology

The core lesion in PD is the progressive loss of dopaminergic neurons in the substantia nigra pars compacta, leading to dopamine depletion in the striatum (caudate and putamen). This disrupts normal basal ganglia circuitry and impairs initiation and scaling of voluntary movement.

• Basal ganglia circuitry:
  • Dopamine acting on D1 receptors facilitates the direct pathway, which promotes movement.
  • Dopamine acting on D2 receptors inhibits the indirect pathway, which normally suppresses movement.
  • Dopamine depletion therefore reduces direct pathway activation and disinhibits the indirect pathway, resulting in excessive inhibition of the thalamus and reduced cortical motor output.
• Lewy bodies: Intracytoplasmic inclusions composed predominantly of misfolded α-synuclein and ubiquitin found in surviving neurons; they are a pathological hallmark of PD and other synucleinopathies.
• Non-dopaminergic involvement:
  • Pathology involves multiple neurotransmitter systems (noradrenergic, serotonergic, cholinergic) and regions (olfactory bulb, dorsal motor nucleus of the vagus, limbic system, neocortex).
  • This explains non-motor symptoms such as hyposmia, sleep disorders, autonomic dysfunction, mood and cognitive changes.
• Etiology:
  • Multifactorial with contributions from genetics, environmental exposures, mitochondrial dysfunction, oxidative stress, impaired protein clearance, and neuroinflammation.

Clinical Presentation

Cardinal Motor Features

Diagnosis is primarily clinical and based on motor signs. The four key motor features of PD are:

• Bradykinesia (required):
  • Slowness of movement with decreased amplitude and speed on repetitive actions (e.g., finger tapping, hand opening/closing).
  • Difficulty initiating movement, reduced arm swing, micrographia, masked facies (hypomimia).
• Rest tremor:
  • Classically a 4–6 Hz “pill-rolling” tremor of the hand, present at rest and attenuated with voluntary movement.
  • Often asymmetric at onset; can involve jaw, legs, but typically spares head/voice compared with essential tremor.
• Rigidity:
  • Increased resistance to passive movement, independent of velocity.
  • May be cogwheel (ratchety) or lead-pipe.
• Postural instability:
  • Impaired postural reflexes leading to falls; typically develops later in the disease course.
  • Assessed with pull test (patient takes multiple or no corrective steps).

Other Motor Features

• Gait disturbance: narrow-based, shuffling gait; decreased arm swing; difficulty turning (en bloc); festination (accelerating short steps).
• Freezing of gait, especially when initiating walking, turning, or approaching narrow spaces.
• Dysarthria (hypophonia, monotonous speech) and dysphagia.
• Motor fluctuations and dyskinesias in advanced stages, particularly related to dopaminergic therapy.

Non-Motor Symptoms

Non-motor manifestations are common, may precede motor signs (prodromal PD), and significantly affect quality of life.

• Neuropsychiatric: depression, anxiety, apathy, fatigue, cognitive impairment progressing to dementia, hallucinations (often visual), impulse control disorders (associated with dopamine agonists).
• Sleep disturbances: insomnia, fragmented sleep, REM sleep behavior disorder (acting out dreams), restless legs, excessive daytime sleepiness.
• Autonomic dysfunction: orthostatic hypotension, constipation, urinary urgency/nocturia, erectile dysfunction, sialorrhea, sweating abnormalities, seborrheic dermatitis.
• Sensory: hyposmia/anosmia, pain, paresthesias.
• Other: weight loss, fatigue, dysphagia-related aspiration risk.

Diagnosis

PD remains a clinical diagnosis. No single laboratory or imaging test confirms idiopathic PD in routine practice.

Clinical Diagnostic Criteria

Contemporary criteria (e.g., MDS Clinical Diagnostic Criteria for PD) emphasize:

• Step 1 – Parkinsonism: bradykinesia plus at least one of rest tremor or rigidity.
• Step 2 – Exclusion criteria: absence of red flags suggesting other causes, such as early severe autonomic failure, early falls, early dementia, supranuclear gaze palsy, cerebellar signs, marked pyramidal signs, or exposure to dopamine-blocking drugs.
• Step 3 – Supportive criteria: clear, substantial response to dopaminergic therapy; levodopa-induced dyskinesias; rest tremor of a limb; presence of olfactory loss or cardiac sympathetic denervation on imaging.

Investigations

• Basic labs: usually normal; used to exclude other causes of parkinsonism or cognitive impairment (e.g., thyroid dysfunction, B12 deficiency).
• Structural neuroimaging (MRI/CT):
  • Often normal in PD; obtained to rule out vascular lesions, tumors, normal pressure hydrocephalus, or atypical parkinsonian syndromes when the presentation is atypical.
• Functional imaging:
  • Dopamine transporter imaging (e.g., DAT-SPECT) can help differentiate degenerative parkinsonism from essential tremor or drug-induced parkinsonism by showing reduced presynaptic dopaminergic uptake.
  • Not required for typical PD but useful when diagnosis is uncertain.
• Olfactory testing: may demonstrate hyposmia; more often used in research than in routine clinical practice.

Differential Diagnosis

• Essential tremor: action/postural tremor, usually symmetric, improves with alcohol, no bradykinesia or rigidity, normal gait.
• Drug-induced parkinsonism: due to dopamine-blocking agents (antipsychotics, metoclopramide); often symmetric; may improve after drug withdrawal.
• Vascular parkinsonism: lower-body predominant gait disturbance, vascular risk factors, imaging with multiple infarcts or extensive white matter disease.
• Atypical parkinsonian syndromes:
  • Multiple system atrophy (MSA): early autonomic failure, cerebellar signs.
  • Progressive supranuclear palsy (PSP): early falls, vertical gaze palsy, axial rigidity.
  • Corticobasal syndrome (CBS): asymmetric cortical signs (apraxia, sensory neglect, alien limb phenomena).
  • Dementia with Lewy bodies (DLB): dementia and visual hallucinations within 1 year of motor symptoms; prominent fluctuations.

Management

Management is individualized, based on patient age, symptom severity, functional impairment, comorbidities, and patient preference. Treatment includes pharmacologic therapy, non-pharmacologic interventions, and in selected patients, surgical options. Shoulder dysfunction, pain, and other musculoskeletal complications are common in PD and require specific attention to prevent disability and falls.[2](https://europepmc.org/article/MED/37259665)

Non-Pharmacologic Management

• Patient and caregiver education: disease course, therapy goals, medication adherence, potential complications.
• Physical therapy: gait and balance training, strength and flexibility exercises, cueing strategies for freezing of gait.
• Occupational therapy: optimizing ADLs, home safety assessment, adaptive devices.
• Speech and language therapy: for hypophonia, dysarthria, and swallowing difficulties (e.g., Lee Silverman Voice Treatment).
• Exercise: regular aerobic and resistance training; evidence suggests beneficial effects on mobility and possibly disease progression.
• Nutrition: adequate fiber and hydration for constipation; timing of protein intake can be adjusted if levodopa absorption is problematic.
• Mental health support: counseling, cognitive behavioral therapy for depression/anxiety.

Pharmacologic Management

Therapy primarily aims to restore dopaminergic function or modulate basal ganglia neurotransmission. Choice of initial therapy depends on age, cognitive status, and symptom profile.

1. Levodopa/Carbidopa

• Mechanism: Levodopa is a dopamine precursor that crosses the blood–brain barrier and is decarboxylated to dopamine; carbidopa inhibits peripheral dopa decarboxylase, increasing CNS availability and reducing peripheral side effects.
• Role: Most effective symptomatic drug; typically first-line in patients >60–65 years or with significant functional impairment.
• Dosing: Individualized; start low and titrate (e.g., 25/100 mg carbidopa/levodopa three times daily) based on tolerability and response.
• Adverse effects: nausea, orthostatic hypotension, confusion, hallucinations, dyskinesias, motor fluctuations (“wearing off,” “on–off” phenomena) with chronic use.

2. Dopamine Agonists

• Examples: pramipexole, ropinirole, rotigotine; apomorphine (rescue for off episodes).
• Mechanism: Direct stimulation of dopamine receptors in the striatum.
• Role: Often used in younger patients to delay levodopa initiation or as adjuncts to levodopa in those with motor fluctuations.
• Adverse effects: nausea, edema, orthostatic hypotension, somnolence, hallucinations, impulse control disorders (pathologic gambling, hypersexuality, compulsive shopping).

3. MAO-B Inhibitors

• Examples: selegiline, rasagiline, safinamide.
• Mechanism: Inhibit monoamine oxidase-B, reducing dopamine breakdown in the brain.
• Role: Mild symptomatic benefit in early disease; can also be used as adjuncts to levodopa to reduce “off” time.
• Adverse effects: insomnia (particularly with selegiline), nausea, orthostatic hypotension; theoretical risk of serotonin syndrome with certain antidepressants.

4. COMT Inhibitors

• Examples: entacapone, opicapone; tolcapone (rarely used due to hepatotoxicity risk).
• Mechanism: Inhibit catechol-O-methyltransferase, decreasing peripheral breakdown of levodopa and prolonging its effect.
• Role: Adjuncts in patients with motor fluctuations and wearing-off phenomena on levodopa.
• Adverse effects: diarrhea, orange discoloration of urine, dyskinesias (from increased levodopa effect), hepatotoxicity (tolcapone).

5. Amantadine

• Mechanism: NMDA receptor antagonist with dopaminergic and anticholinergic properties.
• Role: Modest benefit for tremor and rigidity; especially useful for levodopa-induced dyskinesias.
• Adverse effects: livedo reticularis, ankle edema, confusion, hallucinations.

6. Anticholinergic Agents

• Examples: trihexyphenidyl, benztropine.
• Role: Primarily used for tremor-predominant PD in younger patients; generally avoided in older adults due to cognitive side effects.
• Adverse effects: dry mouth, urinary retention, constipation, blurred vision, confusion, memory impairment.

Management of Non-Motor Symptoms

• Depression: SSRIs or SNRIs; monitor for interaction with MAO-B inhibitors.
• Psychosis/hallucinations: reduce dopaminergic drugs if possible; consider atypical antipsychotics with minimal D2 blockade (e.g., quetiapine, clozapine) or pimavanserin, depending on local practice.
• Cognitive impairment/dementia: cholinesterase inhibitors (e.g., rivastigmine) can be useful.
• Sleep disturbances: melatonin for insomnia or REM sleep behavior disorder; clonazepam used cautiously for REM behavior disorder.
• Autonomic dysfunction: fludrocortisone, midodrine, or droxidopa for orthostatic hypotension; laxatives and increased fiber for constipation; anticholinergic or botulinum toxin therapy for sialorrhea as appropriate.

Surgical and Device-Based Therapies

• Deep brain stimulation (DBS):
  • Targets: subthalamic nucleus (STN) or globus pallidus internus (GPi).
  • Indications: advanced PD with disabling motor fluctuations or dyskinesias despite optimized medical therapy, and good levodopa responsiveness.
  • Benefits: reduces off time, improves dyskinesias, allows reduction in levodopa dose.
  • Limitations: less effect on axial symptoms (speech, balance), non-motor symptoms, or cognitive decline; not suitable for patients with significant dementia or severe psychiatric disease.
• Other emerging therapies: levodopa intestinal gel infusion, focused ultrasound, gene and cell-based therapies under investigation.

Key Clinical Pearls for Medical Students

• Bradykinesia plus rest tremor or rigidity defines parkinsonism; idiopathic PD is the most common cause but is a diagnosis of exclusion.
• Asymmetry at onset (one-sided tremor or rigidity) and a good, sustained response to levodopa strongly support idiopathic PD.
• Non-motor features such as hyposmia, constipation, depression, and REM sleep behavior disorder can precede motor onset by years and are important clues.
• Always review the medication list for dopamine-blocking agents that can cause or worsen parkinsonism.
• Differentiating PD from atypical parkinsonian syndromes is key: look for early falls, early autonomic failure, early dementia, gaze palsy, or cerebellar/pyramidal signs as red flags.
• Motor complications (wearing off, dyskinesias) are common with long-term levodopa therapy, especially in younger-onset patients; consider adjunctive therapies and fractionating doses.
• Shoulder pain, frozen shoulder, and other musculoskeletal problems are common in PD and are often under-recognized; early physiotherapy and targeted treatment help preserve function.[2](https://europepmc.org/article/MED/37259665)
• Management is multidisciplinary: neurology, primary care, physiotherapy, occupational therapy, speech therapy, mental health, and social support all play critical roles.
• Regular follow-up is essential to adjust medications, monitor for motor and non-motor complications, and address safety issues such as falls and swallowing difficulties.